<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02350686</url>
  </required_header>
  <id_info>
    <org_study_id>2014-09-020</org_study_id>
    <nct_id>NCT02350686</nct_id>
  </id_info>
  <brief_title>XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy</brief_title>
  <official_title>Phase II Study of Second Line Capecitabine Plus Oxaliplatin (XELOX) in Patients With Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study of second line capecitabine plus oxaliplatin (XELOX) in patients with advanced
      biliary tract carcinoma after failure of gemcitabine-based chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      XELOX

        -  Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks

        -  Oxaliplatin 130mg/㎡, day 1, every 3 weeks Until disease progression, patient's refusal
           or up to 8 cycles (maximum).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>capecitabine+oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELOX every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles</description>
    <arm_group_label>capecitabine+oxaliplatin</arm_group_label>
    <other_name>xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles</description>
    <arm_group_label>capecitabine+oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age ≥ 18

          2. histologically or cytologically confirmed adenocarcinoma of biliary tract
             (intrahepatic, extrahepatic cholangiocarcinoma, gall bladder cancer and ampulla of
             Vater cancer)

          3. unresectable or metastatic

          4. progression after treatment with first line gemcitabine-based chemotherapy

          5. ECOG performance status of 0~2

          6. measurable or evaluable lesion per RECIST 1.1 criteria

          7. adequate marrow, hepatic, renal and cardiac functions

        Exclusion Criteria:

          1. severe co-morbid illness or active infections

          2. pregnant or lactating women

          3. History of documented congestive heart failure, angina pectoris requiring medication,
             evidence of tranasmural myocardial infarction on ECG, poorly controlled hypertension,
             clinically significant valvular heart disease or high risk of uncontrollable
             arrhythmia

          4. active CNS metastases not controllable with radiotherapy or corticosteroids

          5. known history of hypersensitivity to study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>hoyeong lim, MD,Ph</last_name>
    <email>hoy.lim@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>sungju park</last_name>
    <email>sungju6820.park@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sungju park</last_name>
      <email>sungju6820.park@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Ho Yeong Lim</investigator_full_name>
    <investigator_title>MD, PhD, Division of Hematology-Oncology, Department of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

